Last reviewed 2026-04-20 · How we verify

Baytril (ENROFLOXACIN)

FDA-approved active Small molecule Quality 0/100

Baytril (generic name: ENROFLOXACIN) is a drug. It is currently FDA-approved.

Baytril, also known as Enrofloxacin, is a small molecule antibiotic originally developed by Bayer. It is currently owned by Zoetis, a leading animal health company. Baytril is used to treat various bacterial infections in animals, including respiratory, urinary, and gastrointestinal infections. It is a fluoroquinolone antibiotic, which means it works by inhibiting bacterial DNA gyrase and topoisomerase IV enzymes, ultimately preventing bacterial replication. Baytril is commercially available as a patented product, but generic versions may be available in certain regions.

At a glance

Generic name	ENROFLOXACIN
Modality	Small molecule
Therapeutic area	Immunology
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Pharmacokinetics of Enrofloxacin in Plasma and Urine (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Baytril CI brief — competitive landscape report
Baytril updates RSS · CI watch RSS

Frequently asked questions about Baytril

What is Baytril?

Baytril (ENROFLOXACIN) is a Small molecule drug.

What is the generic name of Baytril?

ENROFLOXACIN is the generic (nonproprietary) name of Baytril.

What development phase is Baytril in?

Baytril is FDA-approved (marketed).

Therapeutic area: All drugs in Immunology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing